Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 27;185(14):2434–2451.e17. doi: 10.1016/j.cell.2022.05.022

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Elsevier Inc.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

SARS-CoV-2-specific memory B cells to mRNA-1273, BNT162b2, Ad26.COV2.S, and NVX-CoV2373 vaccines

(A and B) Representative gating strategy for (A) spike-binding and (B) RBD-binding memory B cells (“MBCs”) (See also Figure S5).

(C and D) Frequency of (C) spike-binding and (D) RBD-binding MBCs from total MBCs elicited after 3.5 and 6 months. Limit of detection = 0.0017. RBD donut graphs represent isotype distribution; IgG (gray), IgA (blue), IgM (yellow), and other (black).

(E and F) Proportion of spike-binding MBCs with (E) activated (CD21⁻CD27⁺) and (F) classical (CD21⁺CD27⁺) phenotypes at 6 months. Data are represented as mean ± SD.

(G and H) Proportion of spike-binding MBCs expressing (G) CD71 or (H) CXCR3 at 3.5 months. Data are represented as mean ± SD.

(I and J) Comparisons between vaccinees and SARS-CoV-2-infected individuals for (I) Spike-binding MBCs and (J) RBD-binding MBCs at 6 months. Data are represented as geometric mean ± geometric SD.

The vaccines are color-coded as per Figure 2. The color-coded bold lines in (C) and (D) represent the geometric mean at each time post-vaccination. Bottom bars show T4 to T5 statistics. Data were analyzed for statistical significance using the Mann-Whitney test ([C], [D]), Kruskal-Wallis (KW) test and Dunn’s post-test for multiple comparisons ([E], [F], [G], [H], [I], [J]0. NS, non-significant. See also Figures S5 and S6.